Tradestie Institutional Equity Comparison Engine
XMAX vs ADIL โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ADIL Overall Edge
ADIL Captures Institutional Edge (2โ0 Pillars ยท 7โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Adial Pharmaceuticals, Inc (ADIL) driven by superior Growth & Margin, Momentum & Technical. Fundamentally, XMAX trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus ADIL at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, XMAX sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against ADIL sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
XMAX N/M vs ADIL N/M Fwd P/E
Growth & Margin Winner
ADIL
Op Margin N/A vs 0.0% ยท YoY N/A vs +0.0%
Momentum & Technical Winner
ADIL
1Y -23.9% vs +1283.9% ยท 52W Pos 47% vs 70%
Options & Structure Winner
Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
XMAX
US Equity
XMAX
Institutional Equity
$6.01
+0.33% 1D
Market Cap
N/A
1M Return
-31.31%
1Y Return
-23.92%
Forward P/E
N/M
Unified AI Score
46.4 / 100
HOLD
Tech 45.0
Fund 49.0
Flow 50.0
Mom 54.0
ADIL
NASDAQ
Adial Pharmaceuticals, Inc
Pharmaceutical Preparations
$5.05
+36.12% 1D
Market Cap
$9.7M
1M Return
+21.69%
1Y Return
+1283.94%
Forward P/E
N/M
Unified AI Score
32.8 / 100
SELL
Tech 5.0
Fund 36.0
Flow 50.0
Mom 44.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
XMAX -23.92%
ADIL +1283.94%
Spread: +210.24 pp (ADIL Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
XMAX TTM Op. Margin: N/A
ADIL TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on XMAX vs ADIL. Trailing 12-month operating profitability (XMAX N/A vs ADIL 0.0%) and valuation multiples (XMAX N/M vs ADIL N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | XMAX | ADIL | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | N/A | $9.7M | Larger Scale | ADIL |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | N/A | +0.0% | Higher Growth | ADIL |
| Operating Margin (TTM) Profitability | N/A | 0.0% | Higher Margin | ADIL |
| Net Profit Margin Profitability | N/A | 0.0% | Higher Margin | ADIL |
| Return on Equity (ROE) Capital Efficiency | N/A | -2011.6% | Higher ROE | ADIL |
| 52-Week Range Position Momentum | 47% ($3โ$9) | 70% ($0โ$7) | Stronger Trend | ADIL |
| Beta / 30D Volatility Risk Regime | 1.90ฮฒ ยท 195% Vol | 0.63ฮฒ ยท 153% Vol | Lower Realized Risk | ADIL |
| Unified Institutional Score Composite Signal | 46.4 / 100 (HOLD) | 32.8 / 100 (SELL) | Higher Composite | XMAX |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full XMAX vs ADIL Buy Guide
XMAX
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
ADIL
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither XMAX nor ADIL registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.